Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 80, n° 6
pages 1640-1649 (juin 2019)
Doi : 10.1016/j.jaad.2019.01.009
accepted : 6 January 2019
Original Articles

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
 

Makenzie L. Hawkins, MSPH a, Matthew J. Rioth, MD a, b, Megan M. Eguchi, MPH a, Myles Cockburn, PhD a, c, d, e,
a University of Colorado Cancer Center, University of Colorado, Aurora, Colorado 
b Department of Medicine-Biomedical Informatics and Personalized Medicine, School of Medicine, University of Colorado, Aurora, Colorado 
c Department of Dermatology, School of Medicine, University of Colorado, Aurora, Colorado 
d Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California 
e Department of Dermatology, Keck School of Medicine of the University of Southern California, Los Angeles, California 

Correspondence to: Myles Cockburn, PhD, 13001 E 17th Place, Campus Box F434, Aurora, CO 80045.13001 E 17th Place, Campus Box F434AuroraCO80045
Abstract
Background

Clinical guidelines for the treatment of melanoma are based largely on the behavior of thicker tumors. As a result, little is known about survival differences among patients with thinner tumors.

Objective

To investigate the variability in survival for American Joint Committee on Cancer stage T1 thin melanoma tumors, defined as tumors less than 1 mm thick at diagnosis.

Methods

This population-based series included 43,008 non-Hispanic whites in whom cutaneous melanoma was diagnosed between 2004 and 2013 from the California Cancer Registry. Survival outcomes were estimated using the Kaplan-Meier method. Cox proportional hazard models were used to estimate risk of death.

Results

Survival for patients with thin ulcerated tumors was comparable to that for patients with stage II tumors, who are currently treated more aggressively. At 12 months, patients with thin ulcerated tumors had approximately 6% lower survival (92.5% [95% confidence interval (CI), 90.6%-93.9%]) compared with patients with thin nonulcerated tumors (98.2% [95% CI, 98.0%-98.3%]). At 24 months, this survival difference increased (85.2% [95% CI, 82.8%-87.4%] vs 96.1% [95% CI, 95.8-96.3%] for those with thin ulcerated and thin nonulcerated tumors, respectively) and a greater than 15% survival difference was seen at 60 months.

Limitations

Previous reports of cancer registry data have noted some evidence of miscoding of thin tumors.

Conclusion

The poorer survival in patients with ulcerated tumors less than 1 mm thick implies the need for additional studies to determine potential benefits of more aggressive treatment.

The full text of this article is available in PDF format.

Key words : melanoma, staging, survival, tumor thickness

Abbreviations used : CI, SEER, SES, SLN, SLNB



 Funding sources: Supported by grant R01CA158407 from the National Cancer Institute and the National Institute of Child Health and Human Development. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; the Centers for Disease Control and Prevention's National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; and the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN2 61201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute. Supported in part by the Population Health Shared Resource of the University of Colorado Cancer Center (P30CA046934).
 Conflicts of interest: None disclosed.
 The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors.
 Reprints not available from the authors.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline